Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial

Abstract

AIMS A guided de-escalation of P2Y12 inhibitor treatment is considered as an alternative treatment strategy in ACS patients undergoing PCI. However, the safety and efficacy of this strategy may differ in diabetic vs. non-diabetic patients. The aim of this study was to compare the outcomes of platelet function testing (PFT) guided de-escalation of dual antiplatelet treatment (DAPT) in ACS patients with and without diabetes mellitus. METHODS AND RESULTS TROPICAL-ACS trial randomized 2610 biomarker-positive ACS patients 1:1 to either standard treatment with prasugrel for 12 months (control group) or to PFT guided DAPT de-escalation. The association and interaction of diabetes on clinical endpoints across treatment groups and on platelet reactivity was investigated. In diabetic patients (n=527, 20.2%), the overall event rates were high and the 1-year incidence of the primary endpoint (cardiovascular death, myocardial infarction, stroke or bleeding ≥ grade 2) did not differ between guided de-escalation and control group patients (12.5% vs. 10.8%; HR 1.17, 95% CI 0.71-1.93, p=0.55). In non-diabetic patients (n=2083, 79.8%), the 1-year incidence of the primary endpoint was lower in the guided de-escalation vs. control group (6.1% vs. 8.5%; HR 0.71, 95% CI 0.52-0.99, p=0.04, pint=0.10) Diabetic patients showed higher platelet reactivity levels in both control (=on prasugrel, p=0.01) and guided de-escalation group (=on-clopidogrel, p=0.005) patients. CONCLUSIONS Although diabetic stat…

Overview

Integrity signals

Registry

Crossref · 10.4244/eij-d-18-01077

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 26 references

Cited by

See all 14

Metadata

Authors
Hein, R., Gross, L., Aradi, D., Rieber, J., Hadamitzky, M., Merkely, B., Huczek, Z., Ince, H., Hummel, A., Baylacher, M., Massberg, S., Trenk, D., & Sibbing, D.
Affiliations
Ludwig-Maximilians-Universität München (DE)
Venue
EuroIntervention
Published
2019-08
Volume
15
Issue
6
Pages
e513-e521
ISSN
  • 1774-024X (ISSN-L)
  • 1969-6213
OpenAlex
W2968073174
Cited by
12
References
26
Citations by year
2025: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Locations
  • EuroIntervention (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
diabetes mellitus, antiplatelet therapy de-escalation, P2Y12 inhibitors, prasugrel, clopidogrel, platelet function testing, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, platelet reactivity, bleeding risk
MeSH terms
Prasugrel Hydrochloride, Diabetes Mellitus, Humans, Platelet Aggregation Inhibitors, Platelet Function Tests, Treatment Outcome, Acute Coronary Syndrome, Percutaneous Coronary Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. https://app.cochat.ai/papers/10.4244/eij-d-18-01077
The paper
Hein, R., Gross, L., Aradi, D., Rieber, J., Hadamitzky, M., Merkely, B., Huczek, Z., Ince, H., Hummel, A., Baylacher, M., Massberg, S., Trenk, D., & Sibbing, D. (2019). Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. EuroIntervention. https://doi.org/10.4244/eij-d-18-01077

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.